首页> 美国卫生研究院文献>other >Functional Characterization and Evaluation of In Vitro Protective Efficacy of Murine Monoclonal Antibodies BURK24 and BURK37 against Burkholderia pseudomallei
【2h】

Functional Characterization and Evaluation of In Vitro Protective Efficacy of Murine Monoclonal Antibodies BURK24 and BURK37 against Burkholderia pseudomallei

机译:鼠单克隆抗体BURK24和BURK37对伯克霍尔德氏菌的体外保护作用的功能表征和评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Burkholderia pseudomallei, the causative agent of melioidosis has been recognized by CDC as a category B select agent. Although substantial efforts have been made for development of vaccine molecules against the pathogen, significant hurdles still remain. With no licensed vaccines available and high relapse rate of the disease, there is a pressing need for development of alternate protection strategies. Antibody-mediated passive protection is promising in this regard and our primary interest was to unravel this frontier of specific mAbs against Burkholderia pseudomallei infections, as functional characterization of antibodies is a pre-requisite to demonstrate them as protective molecules. To achieve this, we designed our study on in vitro-based approach and assessed two mAbs, namely BURK24 and BURK37, reactive with outer membrane proteins and lipopolysaccharide of the pathogen respectively, for their ability to manifest inhibitory effects on the pathogenesis mechanisms of B. pseudomallei including biofilm formation, invasion and induction of apoptosis. The experiments were performed using B. pseudomallei standard strain NCTC 10274 and a clinical isolate, B. pseudomallei 621 recovered from a septicemia patient with diabetic ailment. The growth kinetic studies of the pathogen in presence of various concentrations of each individual mAb revealed their anti-bacterial properties. Minimal inhibitory concentration and minimal bactericidal concentration of both the mAbs were determined by using standards of Clinical and Laboratory Standards Institute (CLSI) and experiments were performed using individual mAbs at their respective bacteriostatic concentration. As an outcome, both mAbs exhibited significant anti-Burkholderia pseudomallei properties. They limited the formation of biofilm by the bacterium and completely crippled its invasion into human alveolar adenocarcinoma epithelial cells. Also, the mAbs were appreciably successful in preventing the bacterium to induce apoptosis in A549 cells. The present study design revealed the protection attributes possessed by BURK24 and BURK37 that has to be further substantiated by additional in vivo studies.
机译:CDC已将类鼻疽病的病原体伯克霍尔德菌(Burkholderia pseudomallei)列为B类选择药物。尽管已经为开发针对病原体的疫苗分子做出了巨大努力,但是仍然存在很大的障碍。在没有可用的许可疫苗和疾病的高复发率的情况下,迫切需要开发替代保护策略。抗体介导的被动保护在这方面是有前途的,我们的主要兴趣是阐明针对Burkholderia pseudomallei感染的特异性mAb的前沿领域,因为抗体的功能表征是证明其为保护性分子的前提。为实现这一目标,我们设计了基于体外方法的研究,并评估了两个mAb(分别与病原体的外膜蛋白和脂多糖反应)的BURK24和BURK37,它们对B的发病机理具有抑制作用。假小肠包括生物膜的形成,侵袭和凋亡的诱导。使用假芽孢杆菌标准菌株NCTC 10274和从患有糖尿病病的败血病患者中回收的临床分离株假芽孢杆菌621进行实验。在各种浓度的每种单克隆抗体存在下,病原体的生长动力学研究表明它们具有抗菌特性。通过使用临床和实验室标准协会(CLSI)的标准确定两种mAb的最低抑菌浓度和最低杀菌浓度,并使用各自的抑菌浓度使用单个mAb进行实验。结果,两种mAb均显示出显着的抗伯克霍尔德菌假mallei特性。他们限制了细菌形成生物膜,并完全破坏了其侵入人肺泡腺癌上皮细胞的能力。同样,单克隆抗体在预防细菌诱导A549细胞凋亡方面也相当成功。本研究设计揭示了BURK24和BURK37拥有的保护属性,必须通过其他体内研究进一步证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号